Seegene has announced plans to launch its new Covid-19 PCR test, Allplex SARS-CoV-2 Fast PCR Assay, later this month.

The new test targets the E, RdRP and N Covid-19 genes, in order to detect the disease regardless of variants, and provides results in 60 minutes.

It is expected to reduce the total turnaround time for mass testing and triple the testing capacity for laboratories and hospitals while eliminating the need for additional instruments.

Seegene stated that the new Covid-19 PCR test’s turnaround time was reduced due to the use of a new enzyme and its innovative extraction-free method.

The enzyme developed by the company reduces PCR process times by half while the extraction-free method removes the sample preparation extraction needed for PCR-based tests.

This helps reduce the total turnaround time for each result, as well as the amount of hands-on processing time.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Seegene chief sales and marketing officer Ho Yi said: “This assay will be the optimised choice for laboratories and hospitals where they conduct large-scale testing as it helps them immediately expand the testing capacity with lessening the burden of healthcare workers.

“For the time being, we plan to target large-scale testing markets in more than 60 countries all across the globe.

“The next step in our journey is to develop a new gold-standard molecular diagnostic assay that fully matches the speed of antigen tests with the same degree of accuracy as PCR test.”

Clinical research conducted in seven countries by 17 laboratories demonstrated that the new Allplex SARS-CoV-2 Fast PCR assay had the same or better accuracy for the detection of Covid-19 compared to other available diagnostic tests.

In a previous development, Seegene received authorisation from Health Canada for its Allplex SARS CoV-2 FluA/FluB/RSV Assay.